NCT04879563Active, not recruitingPhase 2
Artificial Intelligence Supporting CAncer Patients Across Europe - the ASCAPE Project
Source: ClinicalTrials.gov · Last updated 19 Nov 2024 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
ASCAPE (Artificial intelligence Supporting CAncer Patients across Europe) is a collaborative research project involving 15 partners from 7 countries, including academic medical centers, SMEs (small and medium-sized enterprises), research centers and universities, aiming to leverage the recent advances in Big Data and AI (Artificial Intelligence) to support cancer patients' Quality of Life (QoL) and health status. Specifically, ASCAPE aims to provide personalized- and AI-based predictions for QoL issues in breast- and prostate cancer patients as well as suggest potential interventions to their physicians. This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 875351.
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 500 (estimated)
- First submitted
- 30 Apr 2021
- Start date
- 1 Feb 2021
- Primary completion date
- 30 Jun 2024
- Lead sponsor
- Region Örebro County
- Diseases
- Prostate cancer
- NCT number
- NCT04879563
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 500
- From 1 Feb 2021 to the primary completion date, 30 Jun 2024
- 5 sites in 4 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- patients with known medical history of allergy to the wearable material.
Other
- inability to give informed consent
- inability / no access to smartphones, applications or internet services
Who the study is looking for
- breast cancer diagnosis
- no clinical evidence of metastatic disease
- able for curative treatment with surgery with or without oncological treatment.
- prior early breast cancer who are at follow-up with at least 12 months after surgery or chemotherapy (whichever occurred last).
- breast cancer diagnosis (as per self-reported) irrespective of stage and treatment.
- proostate cancer diagnosis
- no clinical evidence of metastatic disease
- able for curative treatment with surgery with or without oncological treatment (SGHA) or radiotherapy (with or without prior surgery) irrespectively the type of radiotherapy (external radiotherapy, brachytherapy, or combination).
- prostate cancer diagnosis (as per self-reported) irrespective of stage and treatment.
Criteria the registry did not label
- The patient selection process varies among the different study sites. Three Hospitals (Sismanogleio General Hospital Athens (SGHA), Örebro University Hospital (ÖUH), Uppsala University Hospital (UUH)) will include patients with newly diagnosed breast- (ÖUH, UUH) or prostate cancer (SGHA, ÖUH) who are eligible for curative treatment with surgery (breast cancer in ÖUH and UUH; prostate cancer in NKUA) or radiotherapy (prostate cancer; ÖUH).
- One Hospital (Barcelona) will include breast cancer survivors (at least 12 months after surgery or chemotherapy) with follow-up through the Hospital.
- Finally, CareAcross will include patients with breast- or prostate cancer through its online platform for patients seeking for the CareAcross services.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (5)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Oncology Department, Hospital Clínic de Barcelona Coordinator of this site? Confirm its status | Barcelona | Spain | Unknown status |
| CareAcross Coordinator of this site? Confirm its status | London | United Kingdom | Unknown status |
| Urology Department, Sismanogleio General Hospital Coordinator of this site? Confirm its status | Athens | Greece | Unknown status |
| Department of Oncology, Örebro University Hospital Coordinator of this site? Confirm its status | Örebro | Sweden | Unknown status |
| Department of Oncology, University Hospital of Uppsala Coordinator of this site? Confirm its status | Uppsala | Sweden | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.